Non-alcoholic fatty liver disease (NAFLD)

NAFLD is currently the most common liver disorder both in the US and Europe. The fatty liver may progress to non-alcoholic steatohepatitis (NASH), which markedly increases the risk of cirrhosis and hepatocellular carcinoma. NAFLD is the hepatic manifestation of the metabolic syndrome and characterizes the majority of patients with type 2 diabetes. 

Objectives

1. To advance our understanding of the prevalence, diagnosis, pathogenesis, prevention and treatment of NAFLD.

2. To enable hepatologists and diabetologists and other specialists in cognate disciplines to interact.

EASD: Official endorsement

  • Approval of the Study group
  • Report of a new Study Group (Diabetologia)

Guidelines for the NAFLD Study Group

The NAFLD Study Group will follow the for ​Guidelines endorsed by the Executive Committee of the EASD (European Association for the Study of Diabetes) on 14 January 2013. 

Our Next Event!
​

REGISTRATION IS STILL OPEN

EGIR & NAFLD STUDY GROUPS 2021 ABSTRACT WEBINAR

EASD-EGIR  Tuesday 7, December
EASD-NAFLD Thursday 9, December
Dear Colleague,
As part of the educational activities of our two EASD study groups (the EGIR- European group for insulin resistance and NAFLD- non-alcoholic fatty liver disease) we are organizing a two-day abstract webinar (program attached)
​

EASD-EGIR
Tuesday 7, December 4:30 PM (Rome)

EASD-NAFLD
Thursday 9, December 4:30 PM (Rome)


​You can register through our websites http://www.egir-group.eu/ and http://nafld.weebly.com/
​
Registration is free, but pre-registration is required. Here is the ZOOM link: https://us02web.zoom.us/webinar/register/WN_YAQ10KdQQ2uGoL8RysRWQQ

After registering, you will receive a confirmation email containing information about joining the webinar.
​
Please, feel free to share this announcement with your colleagues/students.

We look forward to seeing you virtually,
​
The Steering committees of the EGIR-EASD & NAFLD-EASD Study Groups
Picture
Kick-off
​meeting 2013

Finland March 22-23, 2013

Links